Valuation: Talphera, Inc.

Market Cap 55.54M 49.75M 45.89M 41.53M 77.66M 5.29B 78.92M 548M 218M 2.77B 208M 204M 8.77B P/E 2026 *
-4.94x
P/E 2027 * -4.92x
Enterprise Value 55.54M 49.75M 45.89M 41.53M 77.66M 5.29B 78.92M 548M 218M 2.77B 208M 204M 8.77B EV / Sales 2026 *
-
EV / Sales 2027 * 124x
Free-Float
78.59%
Yield 2026 *
-
Yield 2027 * -
1 day-1.83%
1 week+1.90%
Current month-7.76%
1 month-8.55%
3 months-18.32%
6 months+32.31%
Current year-6.14%
1 week 1.05
Extreme 1.05
1.1
1 month 1.03
Extreme 1.03
1.19
Current year 0.69
Extreme 0.6866
1.5
1 year 0.69
Extreme 0.6866
1.57
3 years 0.38
Extreme 0.38
1.61
5 years 0.38
Extreme 0.38
18.4
10 years 0.38
Extreme 0.38
115
Manager TitleAgeSince
Chief Executive Officer 58 06/03/2017
Director of Finance/CFO 56 01/08/2017
Chief Tech/Sci/R&D Officer - 01/10/2024
Director TitleAgeSince
Director/Board Member 60 01/08/2006
Director/Board Member 72 01/02/2010
Chairman 75 11/02/2013
Date Insider Type Main position Quantity % Market Cap. Importance
5/20/26 A Tax

Chief Technology Officer

-4,518 0.0090%
4/2/26 A Tax

Chief Executive Officer

9,938 0.0199%
4/2/26 A Tax

Chief Technology Officer

2,444 0.0049%
Change 5-day change 1-year change 3-year change Capi.($)
-1.83%+1.90%-13.01%+115.47% 55.54M
+6.63%+5.13%+68.86%+145.20% 1,224B
+1.53%+2.84%+47.48%+89.01% 662B
+1.68%+1.96%+29.16%+109.31% 514B
+0.52%+3.15%+54.07%+67.09% 388B
+3.83%-0.62%+69.01%+42.32% 361B
+0.91%+4.20%+34.89%+57.60% 302B
+3.92%+5.74%+8.08%+32.71% 271B
+1.97%+3.01%+57.91%+76.14% 249B
+4.03%+5.36%+39.76%+116.14% 205B
Average +1.63%+2.52%+39.62%+85.10% 417.69B
Weighted average by Cap. +1.76%+3.04%+50.74%+96.54%

Financials

2026 *2027 *
Net sales - 447K 400K 369K 334K 625K 42.57M 635K 4.41M 1.76M 22.28M 1.68M 1.64M 70.56M
Net income -15.61M -13.98M -12.9M -11.67M -21.83M -1.49B -22.18M -154M -61.39M -778M -58.58M -57.33M -2.46B -18.63M -16.69M -15.4M -13.93M -26.06M -1.77B -26.48M -184M -73.29M -929M -69.93M -68.44M -2.94B
Net Debt - -
Projected Income Statement - Annual - Talphera, Inc.
Logo Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
Employees
12
Date Price Change Volume
29/10/26 $1.070 -1.83% 18,810
28/10/26 $1.090 0.00% 60,730
27/10/26 $1.090 +1.87% 31,811
26/10/26 $1.070 -0.93% 42,438
23/10/26 $1.080 +2.86% 76,736
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Talphera, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.070USD
Average target price
3.125USD
Spread / Average Target
+192.06%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Talphera, Inc.
  1. Stock Market
  2. Stocks
  3. TLPH Stock